


CLAIMS

1. A compound of general formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof,



wherein:

M^1 , M^2 , M^4 , M^5 and M^6 are each independently selected from C, $C(R^1)$ and N;

M^3 and M^7 are C;

X^1 and L^1 are each independently selected from $-C(R^5)(R^6)-$ and $-N(R^4)-$;

X^2 and X^3 , when present, are each independently selected from $-C(R^5)(R^6)-$, $-N(R^4)-$ and $-O-$;

ring A is selected from phenyl and 5-6 membered nitrogen-containing heteroaryl;

ring B is absent, X^2 and X^3 are directly connected by a chemical bond;

R^1 , R^2 , R^3 , R^5 and R^6 , when present, are each independently selected from hydrogen, halogen and the following groups optionally substituted with 1-3 Q^1 : C_{1-6} alkyl, $-OR^a$; Q^1 , when present, is independently selected from hydroxy, amino, halogen;


R^4 , when present, is independently selected from hydrogen and C_{1-6} alkyl optionally substituted with 1 to 3 Q^2 ; Q^2 , when present, is independently selected from hydroxy, amino, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkyl, halo C_{1-6} alkoxy;

or X^1 , together with L^1 , forms 3-6 membered monoheterocyclyl ;

R^a , when present, are each independently selected from hydrogen, C_{1-6} alkyl, halo C_{1-6} alkyl, halo C_{1-6} alkoxy; and

m , n , p , q and t are each independently selected from 0, 1, 2, 3, 4 and 5.


- 5 2. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to claim 1, wherein the compound is of the structure shown as general formula (II),



(II)

- 10 wherein M^2 , M^5 and M^6 are each independently selected from CH and N.

3. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to claim 1, wherein the compound is of the structure shown as general formula (III),



(III)

wherein:

ring C is pyrrolidinyl ;

$-(X^2)_p-$ is selected from $-C(R^5)(R^6)-$, $-C(R^5)(R^6)-C(R^5)(R^6)-$, $-N(R^4)-$

$C(R^5)(R^6)-$, $-O-C(R^5)(R^6)-$, $-C(R^5)(R^6)-N(R^4)-$ and $-C(R^5)(R^6)-O-$, and the left chemical bond thereof is connected to ring A and the right chemical bond thereof is connected to X^3 ;

5 $-(X^3)_q-$ is selected from $-C(R^5)(R^6)-$, $-C(R^5)(R^6)-C(R^5)(R^6)-$, $-N(R^4)-C(R^5)(R^6)-$, $-O-C(R^5)(R^6)-$, $-C(R^5)(R^6)-N(R^4)-$ and $-C(R^5)(R^6)-O-$, and the left chemical bond thereof is connected to X^2 and the right chemical bond thereof is connected to carbonyl;

R^2 , when present, is independently selected from hydrogen, halogen and the following groups optionally substituted with 1 to 3 Q^1 : C_{1-4} alkyl and $-OR^a$; Q^1 ,
10 when present, is independently selected from hydroxy, amino, halogen;

R^a , when present, is each independently selected from hydrogen and C_{1-4} alkyl;

R^5 and R^6 , when present, are each independently selected from hydrogen, halogen, C_{1-4} alkyl and C_{1-4} alkoxy;


15 R^4 , when present, is independently selected from hydrogen and C_{1-4} alkyl optionally substituted with 1 to 2 Q^2 ; Q^2 , when present, is independently selected from hydroxy, amino, halogen and C_{1-4} alkoxy;

and

n is 0, 1 or 2.

20

4. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to claim 3, wherein the compound is of the structure shown as general formula (IV),



(IV)

5. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 3-4, wherein:

ring C is pyrrolidinyl;

ring A is selected from phenyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl and tetrazinyl;


R², when present, is independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxy, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, methylamino, dimethylamino, ethylamino, diethylamino, methoxy, ethoxy, propoxy, isopropoxy, trifluoromethyl and trifluoromethoxy;

R⁵ and R⁶, when present, are each independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxy, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, methoxy, ethoxy, propoxy and isopropoxy; and

R⁴, when present, is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and *sec*-butyl.

6. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-5,

wherein:











and







, and the wavy line marked with “1” represents the connection point of ring A to L¹ and the wavy line marked with “2” represents the connection point of ring A to X²;

$-(X^2)_p-$ is selected from $-C(R^5)(R^6)-$, $-C(R^5)(R^6)-C(R^5)(R^6)-$, $-N(R^4)-C(R^5)(R^6)-$ and $-O-C(R^5)(R^6)-$, and the left chemical bond thereof is connected to ring A and the right chemical bond thereof is connected to X^3 ; and

$-(X^3)_q-$ is selected from $-C(R^5)(R^6)-$, $-C(R^5)(R^6)-N(R^4)-$ and $-C(R^5)(R^6)-O-$,
 5 and the left chemical bond thereof is connected to X^2 and the right chemical bond thereof is connected to carbonyl.




7. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-6, wherein the compound
 10 is selected from the following compounds:

No.	Compound	No.	Compound
Compound 1		Compound 2	
Compound 2-1		Compound 3	
Compound 3-1		Compound 4	
Compound 5		Compound 6	


No.	Compound	No.	Compound
Compound 7		Compound 8	
Compound 9		Compound 10	
Compound 11		Compound 11-1	

wherein * represents that a carbon atom is a chiral carbon atom having a single configuration (R configuration or S configuration).

8. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to claim 7, wherein the compound is selected from:

No.	Compound	No.	Compound
Compound 2'		Compound 3'	
Compound 11'			

9. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-2, wherein the compound is of the structure shown as general formula (V),



(V).

10. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-2, wherein:

X^1 is $-N(R^4)-$;

L^1 is $-C(R^5)(R^6)-$;

ring A is selected from phenyl and 5-6 membered nitrogen-containing heteroaryl;

R^2 , when present, is independently selected from hydrogen, halogen and the following groups optionally substituted with 1 to 3 Q^1 : C_{1-4} alkyl and $-OR^a$; Q^1 , when present, is independently selected from hydroxy, amino, halogen;

R^a , when present, is each independently selected from hydrogen and C_{1-4} alkyl;

R^5 and R^6 , when present, are each independently selected from hydrogen, halogen, C_{1-4} alkyl and C_{1-4} alkoxy;

R^4 , when present, is independently selected from hydrogen and C_{1-4} alkyl optionally substituted with 1 to 2 Q^2 ; Q^2 , when present, is independently selected from hydroxy, amino, halogen and C_{1-4} alkoxy; and

n is 0, 1 or 2.

11. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to claim 10, wherein:

ring A is selected from phenyl, pyrrolyl, imidazolyl, pyridinyl, pyrimidinyl, pyridazinyl, 1,3,5-triazinyl and tetrazinyl;


5 R^2 , when present, is independently selected from hydrogen, fluorine, chlorine, bromine, iodine, hydroxy, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, methylamino, dimethylamino, ethylamino, diethylamino, methoxy, ethoxy, propoxy, isopropoxy, trifluoromethyl and trifluoromethoxy;


R^5 and R^6 , when present, are each independently selected from hydrogen, 10 fluorine, chlorine, bromine, iodine, hydroxy, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl, methoxy, ethoxy, propoxy and isopropoxy; and

R^4 , when present, is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and *sec*-butyl.

15

12. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to claim 11, wherein:



and , and the wavy line marked with "1" represents the connection point of ring A to L^1 and the wavy line marked with "2" represents the connection point of ring A to X^2 .

20

13. The compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 10-12, wherein the compound 25 is selected from:

No.	Compound	No.	Compound
Compound 12		Compound 13	
Compound 13-1		Compound 14	
Compound 15		Compound 16	
Compound 17			

14. A pharmaceutical formulation comprising the compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-13, and one or more pharmaceutically acceptable carriers and/or excipients.

15. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-13, and one or more second therapeutically active agents selected from:

a drug for the treatment of pain, which is selected from Nav1.7 channel modulators, opioid analgesics, non-steroidal anti-inflammatory drugs, sedatives,

selective/non-selective cyclooxygenase inhibitors, antiepileptics, antidepressants, local anesthetics, 5-HT receptor blockers, 5-HT receptor agonists, ergot alkaloids, β -receptor blockers, M receptor blockers, nitrates and vitamin K;

a drug for the treatment of cancer, which is selected from mitotic inhibitors, alkylating agents, antimetabolites, antisense DNA or RNA, antitumor antibiotics, growth factor inhibitors, signal transduction inhibitors, cell cycle inhibitors, enzyme inhibitors, retinoid receptor modulators, proteasome inhibitors, topoisomerase inhibitors, biological response modifiers, hormones, angiogenesis inhibitors, cell growth inhibitors, targeted antibodies, HMG-CoA reductase inhibitors and prenyl-protein transferase inhibitors;

a drug for the treatment of neurodegenerative diseases, which is selected from dopamine-mimetics, dopamine receptor agonists, agents affecting dopamine metabolism, NMDA receptor antagonists, adenosine A_{2A} receptor inhibitors, agents affecting DA release and reuptake, central anticholinergics, cholinesterase inhibitors, 5-HT agonists, α_2 adrenergic receptor antagonists, antidepressants, cholinergic receptor agonists, β/γ secretase inhibitors, H3 receptor antagonists and antioxidant agents;

a drug for the treatment of autoimmune diseases, which is selected from antirheumatic drugs, non-steroidal anti-inflammatory drugs, glucocorticoid drugs, TNF antagonists, cyclophosphamide, mycophenolate mofetil and cyclosporine, which is used for alleviating the disease; and

a drug for the treatment of inflammation, which is selected from steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs.

16. Use of the compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-13, in the preparation of a medication for the treatment and/or prevention of a disease or related condition mediated by one or more tyrosine kinases of TRK and/or ROS1, wherein the disease or related condition is selected from one or more of pain, cancers,

inflammation, neurodegenerative diseases and autoimmune diseases.

17. Use of the compound or the pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-13, in the preparation of a medication for the treatment and/or prevention of a disease or related a condition mediated by one or more tyrosine kinases of TRK and/or ROS1, wherein the disease is, for example, a cancer that is at least partially resistant to a therapeutically active agent targeting TRK and/or ROS1.

18. The use of claim 17, wherein the disease mediated by one or more tyrosine kinases of TRK and/or ROS1 is a cancer, wherein the cancer is selected from lung cancer, colon cancer, rectal cancer, prostate cancer, breast cancer, liver cancer, gallbladder cancer, cholangiocarcinoma, leukemia, melanoma, lymphoma, thyroid cancer, multiple myeloma, soft tissue sarcoma, ovarian cancer, cervical cancer, fallopian tube carcinoma, renal cell carcinoma, gastric cancer, gastrointestinal stromal tumor, bone cancer, basal cell carcinoma, peritoneal cancer, dermatofibroma, pancreatic cancer, esophageal cancer, glioblastoma, head and neck cancer, inflammatory myofibroblast tumor, anaplastic large cell lymphoma and neuroblastoma.

19. The use of claim 18, the lung cancer is selected from small cell lung cancer and non-small cell lung cancer.